NYSE:NVS - Novartis Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$88.99 +0.36 (+0.41 %)
(As of 01/21/2019 02:50 AM ET)
Previous Close$88.99
Today's Range$88.70 - $89.21
52-Week Range$72.30 - $94.19
Volume2.75 million shs
Average Volume1.72 million shs
Market Capitalization$205.57 billion
P/E Ratio18.50
Dividend Yield2.14%
Beta0.73
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; QIAGEN N.V.; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; Pfizer; and Conatus Pharmaceuticals Inc. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone41-61-324-1111

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$49.11 billion
Cash Flow$7.5351 per share
Book Value$32.03 per share

Profitability

Net Income$7.70 billion

Miscellaneous

Employees121,597
Outstanding Shares2,310,000,000
Market Cap$205.57 billion
OptionableOptionable

Novartis (NYSE:NVS) Frequently Asked Questions

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

How will Novartis' stock buyback program work?

Novartis declared that its Board of Directors has approved a stock repurchase program on Saturday, April 8th 2017, which permits the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 2.9% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's board of directors believes its stock is undervalued.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) released its earnings results on Thursday, October, 18th. The company reported $1.32 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.31 by $0.01. The company had revenue of $12.78 billion for the quarter, compared to the consensus estimate of $12.88 billion. Novartis had a return on equity of 15.81% and a net margin of 25.98%. The firm's revenue was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.29 earnings per share. View Novartis' Earnings History.

When is Novartis' next earnings date?

Novartis is scheduled to release their next quarterly earnings announcement on Wednesday, January 23rd 2019. View Earnings Estimates for Novartis.

What price target have analysts set for NVS?

15 equities research analysts have issued 1-year price objectives for Novartis' stock. Their forecasts range from $74.71 to $105.00. On average, they expect Novartis' share price to reach $89.2467 in the next twelve months. This suggests a possible upside of 0.3% from the stock's current price. View Analyst Price Targets for Novartis.

What is the consensus analysts' recommendation for Novartis?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 3 sell ratings, 5 hold ratings, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.

Has Novartis been receiving favorable news coverage?

News headlines about NVS stock have been trending somewhat negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Novartis earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days.

Are investors shorting Novartis?

Novartis saw a drop in short interest in December. As of December 31st, there was short interest totalling 1,617,978 shares, a drop of 48.0% from the December 14th total of 3,114,056 shares. Based on an average trading volume of 2,744,509 shares, the short-interest ratio is currently 0.6 days. Currently, 0.1% of the company's stock are short sold. View Novartis' Current Options Chain.

Who are some of Novartis' key competitors?

Who are Novartis' key executives?

Novartis' management team includes the folowing people:
  • Dr. Vasant Narasimhan, Chief Exec. Officer (Age 43)
  • Mr. Harry Kirsch, Chief Financial Officer (Age 54)
  • Mr. Steven Baert, Head of HR (Age 45)
  • Mr. Richard Francis, Chief Exec. Officer of Sandoz (Age 51)
  • Dr. James E. Bradner M.D., Pres of Novartis Institutes for Biomedical Research (Age 47)

Who are Novartis' major shareholders?

Novartis' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Douglas Lane & Associates LLC (0.01%), Welch Group LLC (0.01%), Gofen & Glossberg LLC IL (0.01%), Park National Corp OH (0.01%), Professional Advisory Services Inc. (0.01%) and Confluence Investment Management LLC (0.01%). Company insiders that own Novartis stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis.

Which institutional investors are selling Novartis stock?

NVS stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., Park National Corp OH, Professional Advisory Services Inc., Bourgeon Capital Management LLC, Global Trust Asset Management LLC, Douglas Lane & Associates LLC, Pennsylvania Trust Co and Private Asset Management Inc.. View Insider Buying and Selling for Novartis.

Which institutional investors are buying Novartis stock?

NVS stock was purchased by a variety of institutional investors in the last quarter, including Confluence Investment Management LLC, Advisors Capital Management LLC, Joel Isaacson & Co. LLC, CX Institutional, Weather Gauge Advisory LLC, Diversified Trust Co, Quadrant Capital Group LLC and Nachman Norwood & Parrott Inc. Company insiders that have bought Novartis stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis.

How do I buy shares of Novartis?

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $88.99.

How big of a company is Novartis?

Novartis has a market capitalization of $205.57 billion and generates $49.11 billion in revenue each year. The company earns $7.70 billion in net income (profit) each year or $4.81 on an earnings per share basis. Novartis employs 121,597 workers across the globe.

What is Novartis' official website?

The official website for Novartis is http://www.novartis.com.

How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]


MarketBeat Community Rating for Novartis (NYSE NVS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  415 (Vote Outperform)
Underperform Votes:  483 (Vote Underperform)
Total Votes:  898
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Featured Article: Hedge Funds Explained

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel